You measure the effectiveness of a regulatory intelligence program by tracking how well it converts information into action, specifically whether it reduces submission failures, shortens response times to regulatory changes, and improves the quality of regulatory decisions. The most useful programs are evaluated against a combination of leading indicators (early warning signals) and lagging indicators (outcomes like approval timelines). The questions below break down the key dimensions of that measurement in practical terms.
What metrics are used to evaluate a regulatory intelligence program?
The core metrics for evaluating a regulatory intelligence program fall into three categories: coverage, responsiveness, and impact. Coverage measures whether the program is tracking all relevant regulatory sources. Responsiveness measures how quickly intelligence is gathered, processed, and distributed. Impact measures whether that intelligence actually improves regulatory decisions or outcomes.
In practice, teams typically monitor a combination of the following:
- Time to awareness: How quickly the team identifies a new guideline, consultation, or regulatory change after it is published
- Distribution rate: The percentage of relevant stakeholders who receive intelligence updates in a defined timeframe
- Action conversion rate: How many intelligence items triggered a concrete regulatory or development decision
- Submission success rate: The proportion of submissions accepted without major queries or deficiencies
- Regulatory gap closure: The number of identified compliance gaps that were addressed before they became problems
No single metric tells the full story. A program that delivers fast updates but never influences strategy is not performing well, even if its distribution rate looks strong. The most meaningful evaluation combines process metrics with downstream outcome data.
How does regulatory intelligence reduce submission risks?
Regulatory intelligence reduces submission risks by giving development teams advance notice of changing requirements, reviewer expectations, and common deficiency patterns before a dossier is compiled. When teams understand what regulators are currently scrutinizing, they can build submissions that address those concerns proactively rather than reactively.
Specifically, a well-functioning regulatory intelligence program helps in several ways. It flags updates to guidelines that affect the technical content of a module before the submission deadline. It tracks agency precedents, such as how similar products were assessed, which informs the strength of the regulatory strategy. It also identifies procedural changes, such as updated submission formats or new questions in scientific advice procedures, that could cause delays if missed.
The risk reduction is most visible in the reduction of Day 120 or Day 180 questions in centralized procedures, fewer requests for supplementary data, and lower rates of withdrawal or refusal. Each of these outcomes is traceable back to whether the team had access to current and accurate regulatory intelligence at the right stage of development.
What’s the difference between reactive and proactive regulatory intelligence?
Reactive regulatory intelligence responds to changes after they have been published or enforced, while proactive regulatory intelligence anticipates changes before they take effect by monitoring consultations, policy trends, and agency signals. The distinction matters because reactive programs protect against known risks, while proactive programs create strategic advantages.
Reactive regulatory intelligence
A reactive approach means the team learns about a new guideline when it is finalized and then adjusts its documentation or strategy accordingly. This is better than having no intelligence function at all, but it often means costly late-stage changes. For example, discovering a new safety data requirement after a clinical program is underway can force expensive protocol amendments.
Proactive regulatory intelligence
A proactive approach involves monitoring draft guidelines, attending scientific workshops, tracking agency consultation outcomes, and engaging with industry associations during the policy development phase. Teams using this approach can shape their programs and dossiers around requirements that are not yet in force but are clearly coming. In a fast-moving regulatory environment like the EU in 2026, where both medicinal product and medical device legislation continues to evolve, the gap between reactive and proactive programs is widening in terms of competitive advantage.
How often should a regulatory intelligence program be reviewed?
A regulatory intelligence program should be reviewed at minimum on a quarterly basis, with a more comprehensive annual review. Quarterly reviews catch gaps in source coverage or workflow bottlenecks before they affect live projects. The annual review assesses whether the program’s scope still matches the company’s pipeline and geographic regulatory footprint.
Outside of scheduled reviews, the program should be evaluated whenever a significant regulatory event occurs, such as a major guideline revision, a failed submission linked to an intelligence gap, or a structural change in the regulatory landscape like new legislation coming into effect. These event-driven reviews are often the most valuable because they test the program against real outcomes rather than theoretical benchmarks.
For early-stage companies or startups entering regulated markets for the first time, even a lightweight review cycle is better than none. The goal is to build a feedback loop where intelligence failures are identified and corrected before they repeat.
What tools support the measurement of regulatory intelligence outcomes?
The tools that support measurement of regulatory intelligence outcomes range from purpose-built regulatory information management systems to simpler shared tracking tools, depending on the organization’s size and complexity. What matters most is that the tool captures both the intelligence inputs and the decisions or actions they influenced.
Commonly used tools and approaches include:
- Regulatory information management systems (RIMS): Platforms that centralize regulatory intelligence, track submission timelines, and link intelligence items to specific projects or dossiers
- Horizon scanning databases: Subscription services that aggregate updates from multiple regulatory agencies and flag items by therapeutic area or product type
- Internal trackers: Spreadsheet or project management tools that log intelligence items, assign owners, set response deadlines, and record outcomes
- Regulatory agency portals: Direct monitoring of EMA, FDA, and other agency websites for guideline publications, consultation launches, and meeting minutes
The choice of tool should be driven by the volume of intelligence the team needs to process and the number of stakeholders who need access. Measurement only works if the system records not just what information was received but what happened as a result of it.
Who is responsible for measuring regulatory intelligence effectiveness?
Responsibility for measuring regulatory intelligence effectiveness typically sits with the Head of Regulatory Affairs or a designated Regulatory Intelligence Lead, but meaningful measurement requires input from multiple functions. Regulatory affairs owns the process, but development, quality, and senior leadership all contribute data points and benefit from the outputs.
In practice, this means the regulatory affairs function defines the metrics and owns the review process, while project teams provide feedback on whether intelligence was timely and relevant to their work. Senior leadership uses outcome metrics, such as submission success rates and time-to-approval, to assess the program’s return on investment.
For smaller organizations without a dedicated regulatory intelligence function, this responsibility often falls to the regulatory affairs manager or an external consultancy partner. In those cases, it is especially important to define accountability clearly, since measurement tends to fall away when no one owns it explicitly.
How Starodub Supports Your Regulatory Intelligence Strategy
Building and measuring a regulatory intelligence program is challenging, especially for companies entering complex markets like the EU without an established regulatory infrastructure. At Starodub, we help biopharmaceutical and medical device companies design regulatory intelligence approaches that are practical, measurable, and directly tied to submission outcomes. Our support includes:
- Defining the right metrics for your program based on your pipeline stage and product type
- Mapping relevant regulatory sources and setting up monitoring workflows for your specific therapeutic area or device category
- Translating regulatory intelligence into actionable guidance for your development and quality teams
- Reviewing and strengthening existing intelligence programs to close coverage gaps before submissions are filed
- Providing proactive horizon scanning as part of ongoing regulatory strategy support
With over 400 completed projects and a team of specialists across medicinal products and medical devices, we bring the depth of experience needed to turn regulatory intelligence into a genuine competitive advantage. If you want to strengthen your regulatory intelligence program or assess how well your current approach is working, get in touch with Starodub to discuss how we can support your goals.
Related Articles
- What is the difference between regulatory intelligence and regulatory affairs?
- Why is preclinical to clinical transition so critical?
- What are the biggest GMP compliance challenges for biotech startups?
- How do you integrate quality by design into regulatory strategy?
- How do you create a regulatory pathway strategy for new drugs?
This content was generated with the help of AI and it may contain mistakes
